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Summary
Helminth parasites infect an alarmingly large proportion of the world’s
population, primarily within tropical regions, and their ability to down-
modulate host immunity is key to their persistence. Helminths have
developed multiple mechanisms that induce a state of hyporesponsiveness
or immune suppression within the host; of particular interest are mecha-
nisms that drive the induction of regulatory T-cells (Tregs). Helminths
actively induce Tregs either directly by secreting factors, such as the TGF-
b mimic Hp-TGM, or indirectly by interacting with bystander cell types
such as dendritic cells and macrophages that then induce Tregs. Expan-
sion of Tregs not only enhances parasite survival but, in cases such as
filarial infection, Tregs also play a role in preventing parasite-associated
pathologies. Furthermore, Tregs generated during helminth infection have
been associated with suppression of bystander immunopathologies in a
range of inflammatory conditions such as allergy and autoimmune dis-
ease. In this review, we discuss evidence from natural and experimental
infections that point to the pathways and molecules involved in helminth
Treg induction, and postulate how parasite-derived molecules and/or
Tregs might be applied as anti-inflammatory therapies in the future.
Keywords: immune regulation; immunomodulators; inflammation;
therapy.
Introduction
Helminth worm parasite infections currently afflict one-
quarter of the world’s population,1,2 the majority of
whom are located in resource-poor tropical countries.
However, before sanitation improvements and industrial-
ization became more widespread in the last century, the
prevalence of helminths was likely to be high across the
globe. Alongside the disappearance of helminth infections
from the higher-income countries, there have however
been sharp rises in a suite of inflammatory autoimmune
and allergic disorders. One possibility, suggested by the
‘hygiene hypothesis’ and more recently the ‘old friends
hypothesis’ is that helminths are one of the key environ-
mental influences, along with members of the microbial
world, that dampen immune reactivity to innocuous
bystander antigens.3!6 While the relative importance of
each environmental factor in restraining inflammatory
processes has yet to be established, the ability of many
helminth parasites to downregulate the host immune sys-
tem suggests that they may play a major role in regulating
immune disorders in humans.7
Abbreviations: Ab, antibody; Ag, antigen; ANA, anti-nuclear antibodies; Breg, regulatory B-cells; CTLA-4, cytotoxic T-lympho-
cyte-associated protein 4; DC, dendritic cell; ES, excretory/secretory product; Foxp3, forkhead box P3; GITR, glucocorticoid-in-
duced tumour necrosis factor receptor; HDM, house dust mite; HES, H. polygyrus excretory-secretory product; Hp-TGM,
H. polygyrus TGM (TGF-b mimic); IBD, inflammatory bowel disease; ICOS, inducible T-cell co-stimulator; IDO-1, indolamine
2,3-dioxygenase; IFN-c, interferon gamma; iTregs, induced Tregs; MS, multiple sclerosis; NOD, non-obese diabetic; nTregs, natu-
ral Tregs; OVA, ovalbumin; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PP, Peyer’s patch;
pTreg, peripheral Tregs; RA, retinoic acid; RORct, RAR-related orphan receptor gamma; SEA, soluble egg antigens; TGF-b,
transforming growth factor beta; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; Tr1, type 1 regulatory cells; TSO,
Trichuris suis ova
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Immune regulation by helminths acts at many levels to
interfere with innate antigen sensitization, induction of
adaptive immunity, and mobilization of effector mecha-
nisms.7 One of the most prominent pathways for parasite
immunomodulation is through regulatory T-cells (Tregs).
Tregs are classified by their expression of the transcrip-
tion factor Foxp3 (FOXP3 in humans) and can express a
number of surface markers that are key for their function,
including CD25, cytotoxic T-lymphocyte-associated pro-
tein 4 (CTLA-4), inducible T-cell co-stimulator (ICOS)
and T-cell immunoreceptor with Ig and ITIM domains
(TIGIT).8 In both mouse and human studies, Tregs are
often defined as CD3+ CD4+ CD25+ Foxp3+ cells,
although Treg cells comprise a diverse population. During
development, the first set of Tregs are formed in the thy-
mus, making up the natural Treg population (nTreg),
while a second type of Tregs can be induced in the
periphery from na€ıve CD4 T-cells [induced Tregs (iTreg)/
peripheral Tregs (pTreg)] in the presence of specific
cytokines such as interleukin (IL)-2 and transforming
growth factor beta (TGF-b); however, the expression of
Foxp3, and indeed regulatory activity, is variable depend-
ing on the level of demethylation at the Foxp3 locus, and
recent studies have identified a number of Treg subtypes
delineated by CD25, Foxp3 and the epigenome.9 Regula-
tory activity can also be found in other lymphocyte sub-
sets, such as the Foxp3!IL-10+ Tr1 cells (previously
defined as Th310), although their role in controlling
immune responses in helminth infection has yet to be
established.
Regulatory T-cells are critical in the prevention of
autoimmunity and other forms of immune dysregulation,
therefore these cells are likely to allow the parasite to not
only survive for longer but also protect the host from a
potentially pathogenic immune response. Hence, a large
proportion of helminth-infected individuals do not
mount an inflammatory response to the parasite, which
otherwise would cause ‘collateral damage’ in the infected
tissues.
Activity of Tregs in human helminth infection
In humans, strong links have frequently been identified
between helminth infection and Treg cell activity, particu-
larly in individuals who are asymptomatic or hypo-re-
sponsive during infection (Table 1). It is important to
note that in human studies, unlike in laboratory models,
co-infection with other pathogens is common, and there
is great variability in the frequency and intensity of expo-
sure to infection. Despite these confounding factors, how-
ever, some clear relationships have emerged.
In the case of Schistosoma mansoni, infection is associ-
ated with elevated numbers of FOXP3-expressing Tregs,
and these cells are also more active during helminth
infection as indicated by expression of programmed cell
death protein 1 (PD-1) and CD45RO. However, after
clearance with the anti-schistosomal drug Praziquantel,
this population returns to baseline.11 An increase in
nTregs in addition to expanded IL-10 producing Tr1 cells
and Th17 cells has been shown in filarial infected individ-
uals in comparison to uninfected controls.12 During filar-
ial infections, peripheral T-cells are typically unresponsive
to parasite antigen, but responses could be rescued
in vitro by depletion of CD25(high) Tregs.13 There is also
evidence to suggest that Tregs are important in prevent-
ing parasite-associated pathologies. In patients infected
with Wuchereria bancrofti, the major causative agent of
lymphatic filariasis, those with lymphoedema have signifi-
cantly enhanced Th1 and Th17 responses and lower Treg
levels in comparison to asymptomatically infected indi-
viduals,14 while in hyper-reactive onchocerciasis (river
blindness) there is a deficiency in FOXP3+ CD25(high)
Tregs.15 A recent study on rural Indonesians infected with
soil-transmitted helminths showed that CTLA-4 and
CD38, HLA-DR, ICOS or CD161 co-expressing Tregs
were expanded compared with both urban-dwelling Euro-
peans, and urban-residing Indonesians, excluding ethnic-
ity as a major factor for this difference.16
Interestingly, both FOXP3!IL-10+ Tr1 and FOXP3+
Tregs are associated with an isotype switch from IgE to
IgG4 in vitro and during helminth infection.17 IgG4, which
does not exist in the mouse, is a strongly anti-inflammatory
isotype as it interacts poorly with cell-bound Fc receptors,
and also is functionally monovalent due to interchange
between heavy-light chain half-molecules following secre-
tion by B-cells.18 Notably, IgG4 is promoted by IL-10 and
competes for the same epitopes as the strongly anti-para-
sitic IgE isotype, thus suppressing IgE-dependent allergic
responses. During helminth infection, individuals have
high levels of both IgG4 and IgE,19 with greater IgG4 : IgE
ratios in asymptomatic infections with high Treg activity.
These studies are supported by treatment with anthelmintic
drugs, which rapidly reduce circulating IgG4 levels indicat-
ing another mechanism by which Tregs are involved in
immunosuppression by helminths.20,21
At a broader level, poor BCG vaccine responses have
been found in helminth-infected individuals, as BCG vac-
cinees show suppressed inflammatory cytokine profiles to
purified protein derivative (PPD/tuberculin) antigen and
strong TGF-b production, both of which are reversed by
anthelmintic treatment.22 Tregs are implicated in the poor
BCG vaccine response, as evidenced by the reduced
in vitro T-cell proliferative responses to both BCG and
malaria, and is recovered once Tregs are removed from
these cultures.23 A more recent study on tuberculosis-in-
fected migrants in the UK showed that those who were
co-infected with helminths had a higher Treg frequency
and lower interferon (IFN)-c+ CD4 T-cells than those
without a helminth infection, and furthermore that
anthelmintic treatment reversed this effect.24
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Overall this body of evidence supports a central role
for parasite-induced Tregs in immune regulation by hel-
minths. Understanding the mechanisms by which this
induction occurs may provide essential knowledge for
anti-helminth vaccinations and drug treatments.
Mouse models of infection – expansion and
manipulation of Tregs
Many mouse helminth models also show an expansion
in Tregs, both from activating the nTreg population as
well as de novo induction of pTregs, with significant
increases by 3–7 days post-infection.25!29 For example,
both Litomosoides sigmodontis and Heligmosomoides poly-
gyrus infections drive an early Treg expansion that is
primarily made up of nTregs.25,28 In addition, induc-
tion of early Foxp3+ cells by the filarial nematode Bru-
gia malayi requires live, rather than heat-killed,
parasites.26 In conjunction with a quantitative expansion
of host Tregs, helminths also induce expression of acti-
vation markers and cytokines including CD103, CTLA-4
and TGF-b, indicating that not only are Tregs induced
but they may also express a more suppressive pheno-
type.25,27
Helminth-induced Tregs are essential for long-term
parasite survival within the immunocompetent host as
removal of Tregs can result in clearance of the infection,
whereas expansion of the Treg compartment with IL-2
renders the host more susceptible.30 The strength of effect
depends on the specific mouse model of helminth infec-
tion and the different depletion/induction methods
employed, as summarized in Table 2. One approach has
been to use antibody depletion of CD25+ cells (clone
PC61), which removed most but not all Tregs. As CD25
is also expressed on activated effector cells, the anti-CD25
is given before infection; Treg depletion in this manner
increased host Th2 cytokine responses and enhanced par-
asite killing.31!36 Additional anti-CTLA-4 (clone UC10-
4F10-11) or anti-glucocorticoid-induced tumour necrosis
factor receptor (GITR) (DTA-1) inhibition alongside
anti-CD25 showed a further enhanced worm killing and
elevation of Th2 cytokine responses, which may be attrib-
uted to ‘reawakening’ the effector T-cell population in
the absence of Treg influence.32,37,38
Table 1. Human helminth Treg associations
Human disease
[pathogen(s)] Evidence for Tregs Treg type/markers used Reference
Ascariasis (Ascaris
lumbricoides)
Blood samples from infected individuals had higher
Treg numbers compared with uninfected controls
CD4+ CD25+ 129
Hookworm infection
(Necator americanus)
Higher levels of circulating Tregs compared with
healthy non-infected donors
CD4+ CD25+ FOXP3+ also expressed CTLA-4,
GITR, IL-10, TGF-b and IL-17
130
Lymphatic filariasis
(Wuchereria bancrofti)
(Wuchereria bancrofti
and Mansonella
perstans)
Patients with lymphoedema had lower Treg levels
compared with asymptomatically infected individuals
PBMCs measured for FOXP3, GITR, TGF-b
and CTLA-4 by RT-PCR
14
Infected individuals had significantly increased
frequencies of aTreg/Tr1 and nTreg compared with
healthy controls
aTreg/Tr1 were CD4+ IL-10+ FOXP3!
nTregs were CD4+ CD25+ FOXP3+CD127!
12
(Brugia timori) Asymptomatic microfilaraemics showed stronger Treg
activity
CD4+CD25(hi) cells depleted in vitro 13
Onchocerciasis
(Onchocerca volvulus)
Hyper-reactive onchocerciasis patients have deficiency
in Tregs
CD4! FOXP3+ CD25(hi) 15
Schistosomiasis
(Schistosoma mansoni)
Elevated FOXP3-expressing Tregs, expression of
activation markers, anti-helminth treatment Treg
numbers return to baseline
CD3+ CD4+ CD25+ 11
(Schistosoma
haematobium)
Increased active Treg frequency, after anti-schistosome
treatment Treg numbers decrease but suppressive
capacity remains
CD4+ CD25hi FOXP3+ 131
Strongyloidiasis
(Strongyloides
stercoralis)
Tregs increased in patients with HTLV-1 co-infection
compared with Strongyloides infection alone
CD4+ CD25+ FOXP3+ in PBMC 132
Treg numbers increased in the duodenum of co-
infected patients compared with healthy controls
FOXP3 expression by IHC 133
Taeniasis/Cysticercosis
(Taenia solium)
Significantly increased frequency of Tregs in patients
with neurocysticercosis compared with healthy
controls
CD4+ CD25high FOXP3+(Treg)
CD4+ CD25high IL-10+
(Tr1)
134
aTreg/Tr1, adaptive Treg; CTLA-4, cytotoxic T-lymphocyte-associated; GITR, glucocorticoid-induced tumour necrosis factor receptor-related pro-
tein; HTLV-1, human T-cell lymphotropic virus type 1; IHC, immunohistochemistry; nTreg, natural Treg; PBMC, peripheral blood mononuclear
cell; RT-PCR, reverse transcription polymerase chain reaction.
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A second approach has been to fully deplete Tregs in
transgenic mice expressing the diphtheria toxin receptor
(DTR) under the Foxp3 promoter. Toxin administration
to these mice showed that Treg depletion during the early
stages of infection may induce protective immunity; how-
ever, depletion at the later stages shows enhanced host
pathology and lack of worm expulsion.29,30,39!41 The dif-
fering results between antibody depletion and DTR mice
may be explained by the residual Treg population in the
former scenario, and indicate that a basal level of Tregs
may be essential for controlling host pathology and per-
mitting a coherent Th2 response to develop in the face
of, for example, IFN-c responses against commensal bac-
teria. Furthermore, complete Treg depletion in DTR mice
is only possible for short periods of time due to increased
mortality, rendering it difficult to determine the role of
Tregs during the full time course of a helminth infection.
As summarized in Table 2, in helminth models such as
H. polygyrus, L. sigmodontis, Schistosoma japonicum and
Strongyloides ratti, Tregs have been shown experimentally
to be important for parasite survival; however, this is not
the case for other species such as Trichuris muris, which
dramatically reduces the proportion of Tregs during
infection and Treg depletion in this model has no effect
Table 2. Mouse parasite Treg interventions
Parasite
Mouse
strain Treatment Role of Tregs Reference
Brugia pahangi BALB/c CD25 depletion Depleting CD25-expressing cells increased Ag-specific Th2
responses
31
Heligmosomoides
polygyrus
C57BL/6 DEREG Early depletion of Tregs did not affect worm burden but Th2
responses were enhanced
27
BALB/c Recombinant IL-2:anti-IL2
complex
Worm persistence increased with increased Treg numbers 30
BALB/c Foxp3.LuciDTR on days 4, 6, 8
and 10
Increased CD4+ T-cell activation and pathology
C57BL/6 Foxp3.LuciDTR on days
14!26 every 2 days
No change to parasite burden despite increased Th2 responses
Litomosoides
sigmodontis
BALB/c Ab depletion – anti-CD25
(PC61) and anti-GITR
Dual depletion results in increased killing of the parasites and
enhances IL-4, IL-5 and IL-10 responses
32
BALB/c Ab depletion – anti-CD25
(PC61) and anti-CTLA4
(UC10-4F10-11)
Dual depletion results in enhanced parasite killing, cytokine
responses unaffected
135
Schistosoma
japonicum
BALB/c Ab depletion – anti-CD25 Reduced Treg numbers were associated with reduced worm burden
and increased IFN-c
33
BALB/c Ab depletion – anti-CD25 and
anti-CTLA-4
Dual depletion results in enhanced parasite killing 37
Schistosoma
mansoni
C57BL/6 Ab depletion – anti-CD25
(PC61) on day !3 and day
35
Enhanced egg destruction, increased pathology 34
C57BL/6 Ab depletion – anti-CD25
(PC61)
Tregs control Th2 colonic granulomas and reduce pathology
during infection
136
Strongyloides
ratti
BALB/c DEREG mice Early depletion of Tregs improved worm expulsion and Th2
responses
29
BALB/c CTLA-4 blockade Moderately increased Th2 and decreased Th1, limited
enhancement to worm expulsion
BALB/c
and
C57BL/6
DEREG mice Early depletion of Tregs improved worm expulsion in BALB/c
mice but not C57BL/6 due to low IL-9 production in this strain
40
Trichinella
spiralis
C57BL/10 Ab depletion with PC61 Enhanced Th2 cytokine response to parasite Ag, no significance on
larval burden
35
Trichuris muris C57BL/6 Ab depletion – PC61 (anti-
CD25) and anti-GITR
Treg depletion results in increased gut pathology but only anti-
GITR results in earlier worm expulsion
36
C57BL/6 DEREG mice Early Treg depletion enhances ability to clear the parasite, late Treg
depletion reduced worm clearance. Both treatments resulted in
enhanced Th2 responses
41
Ab, antibody; Ag, antigen; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; DEREG, ‘depletion of regulatory T-cell’ mouse strain using diphtheria
toxin-induced ablation of Foxp3+ cells; Foxp3.LuciDTR, express knocked-in diphtheria toxin receptor, although a different line function similar to
DEREG mice; GITR, glucocorticoid-induced tumour necrosis factor receptor-related protein; IFN-c, interferon gamma; Treg, regulatory T cell.
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on worm survival.42!44 Clearly, helminths have adopted
multiple strategies to evade host immunity, and therefore
not all species are reliant on the induction of Tregs for
survival within the host, and Treg-directed mechanisms
may be more or less important according to the genotype
of the host.40,45
Pathways by which helminths induce Tregs:
directly and indirectly
Upon infection, many helminths drive an expansion or
recruitment of nTregs during the early stages as indicated
by Helios+ staining,30,46 while nTreg depletion using anti-
CD25+ antibody prior to infection shows that these cells
have a role in parasite persistence.28 Treg expansion in H.
polygyrus-infected mice is greatest in the Peyer’s patches
(PP) that are in contact with the parasite, indicating that
secreted products may act in a local manner to promote
Treg expansion.47 While it is not known what specifically
drives the expansion of nTregs, there have been many
studies looking at the factors that increase overall Treg
numbers during helminth infection indicating specific
pathways by which iTreg/Tr1 cells are induced,48 and
these are summarized in Fig. 1.
Many helminths secrete a plethora of proteins that are
able to interact with the host, in the case of H. polygyrus
3
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Figure 1. Overview of events in Treg expansion by helminths. (1) Early expansion of natural regulatory T-cells (nTreg) by helminths within the
first 3–7 days. (2) Helminth excretory!secretory (ES) products induce na€ıve CD4+ T-cells to become Tregs. (3) ES products polarize dendritic
cells (DCs) towards a tolerogenic phenotype capable of inducing Tregs. (4) M2 macrophage polarization following IL-33 release by damaged
epithelium, which then induce Tregs through an undefined mechanism. (5) Helminth proximity to Peyer’s patch (PP) causes Treg expansion. It
is as yet unclear whether Treg events (1)!(4) occur in either or both the lamina propria of the small intestine and the draining mesenteric lymph
nodes, and hence no distinction is made in this figure.
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several hundred proteins have been identified in the
excretory-secretory products (HES)49 and, furthermore,
these products are able to induce Tregs from na€ıve
CD4+ T-cells in vitro.50 Further analysis identified the
active protein, named Hp-TGM [H. polygyrus TGM
(TGF-b mimic)], which mimics the function of TGF-b
by binding to the TGF-b receptors and inducing Smad
signalling.51 Although Hp-TGM has no structural homol-
ogy with mammalian TGF-b, it is a potent inducer of
mouse and human Foxp3+ Treg cells in vitro. Elabora-
tion of a factor that drives Treg induction argues that
their expansion during helminth infection is not merely
a host homeostatic mechanism to rein in overstimulation
but an adaptive evolutionary strategy on the part of the
parasite to maximize their survival in an immune envi-
ronment.
Interestingly, Hp-TGM is part of a larger gene family
made up of 10 members based on a similar sequence,
with multiple variants able to induce Tregs.52 This redun-
dancy indicates that TGF-b mimicry is a central survival
ploy by this parasite. However, other helminths appear to
depend upon host TGF-b to indirectly induce Tregs. For
example, in S. mansoni infection, soluble egg antigens
(SEA) are able to upregulate host cell TGF-b secretions
and induce Foxp3+ Tregs in a TLR2-dependent man-
ner.34,53
Further examples substantiate that helminths and their
products act on bystander cell types, which are then able
to induce Tregs in an indirect manner. One such hypoth-
esized mechanism is through the induction of tolerogenic
dendritic cells (DCs) that express a range of immunosup-
pressive factors, including IL-10, indolamine 2,3-dioxyge-
nase (IDO), programmed death-ligand 1 (PD-L1),
retinoic acid (RA) and TGF-b, which are known to drive
na€ıve T-cells towards a Treg phenotype.54,55 This pathway
has been implicated in Trichinella spiralis infection in
which DCs exposed to muscle larvae excretory/secretory
(ES) product are able to expand IL-10 and TGF-b-pro-
ducing Foxp3+ Tregs in an IDO-1-dependent manner.56
Bone marrow-derived DCs treated with H. polygyrus ES
also have reduced co-stimulatory molecule and cytokine
expression, and these cells are able to induce IL-10-secret-
ing T-cells (Tr1, regulatory cells) capable of suppressing
effector T-cell responses.57
An emerging area of interest for Treg induction in vivo
relates to the role of alarmins and tissue-derived cytokines
in promoting the regulatory environment. In addition to
factors secreted by the parasites, the epithelial damage
caused by helminths results in release of alarmins such as
TSLP and IL-33,58,59 which may also be involved, indi-
rectly or directly, in expanding Treg numbers during
infection. For example, macrophages express ST2, a
receptor for IL-33, and in the presence of this cytokine
can be polarized to an M2 phenotype leading to IL-10
upregulation and consequent Treg expansion.60
Treg locations: subtypes and surface markers
Helminths are able to infect a range of tissues outside of
the gut, including the lung, pleural cavity, peritoneal cav-
ity and liver.26,38,46,61!66 In each of these different tissue
sites, the immune environment these helminths encounter
will be unique, with tissue-specific immunological proper-
ties including Treg features.67,68 While our understanding
of helminth!Treg interactions in the tissues is still lim-
ited, there are certainly conserved markers of Treg activa-
tion that are induced in multiple helminth-tissue settings.
Expression of CD103, a beta integrin associated with
tissue residency, is shown to be upregulated on Tregs in
the liver,63,64 peritoneal cavity,26 large intestine61 and
small intestine25 during helminth infection compared
with steady-state. Upregulation of CD103 on Tregs may
be a conserved mechanism seen in B. malayi, H. polygyrus
and S. mansoni infection (Fig. 2), indicating that reten-
tion of Tregs in the tissues is important for their function
during helminth infections.25,26,61,63,64
Co-inhibitory molecules are commonly upregulated by
helminth infection. CTLA-4 (also referred to as CD152) is
upregulated on Tregs in many infections, including
B. malayi, L. sigmodontis, S. mansoni and T. spi-
ralis.26,38,62,65 When CTLA-4, a member of the CD28 family,
binds to CD80 or CD86 on DCs they become tolerogenic,
and thus downstream T-cell responses are inhibited. Inter-
estingly, the checkpoint inhibitor GITR is also upregulated
during helminth infection. GITR functions as a Treg inhibi-
tor when bound to its ligand, GITRL, which allows the acti-
vation and expansion of T effector cells. It has been shown
that stimulating GITR and thus decreasing Treg responses
during L. sigmodontis infection causes increased Th2 num-
bers and cytokine output.66 GITR is also upregulated during
S. mansoni and L. sigmodontis infection.38,62 Furthermore,
other co-inhibitory molecules can also be found on the sur-
face of Tregs responding to helminth infection including
PD-1 and ICOS, which indicate that not only are Tregs
expanded during helminth infection but are also potentially
more actively suppressive.38,46,62
An emerging paradigm has been that Treg co-expres-
sion of transcription factors previously associated with Th
effector subsets enables them to co-migrate to the same
sites and thereby fulfil their suppressive action. For exam-
ple, RAR-related orphan receptor gamma (RORct), a
transcription factor that typically defines Th17 cells, is
expressed on a group of Tregs found in the large intes-
tine.69 A recent study has indicated that this unusual sub-
type is also involved in the regulation of Th2 responses,
an idea that is supported by RORctfl/flFoxp3cre mice,
which were able to expel H. polygyrus more efficiently
than C57BL/6 counterparts.69
As discussed above, innate alarmins such as IL-33 have
a major impact on the T-cell population. Hence, the
report of ST2 (IL-33R) expressing Tregs in the colon is
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particularly interesting.70 However, ST2-deficient mice
have normal Treg responses to H. polygyrus infection and
indeed are more susceptible to the parasite,71 highlighting
the contrasting role of IL-33 in different tissues and set-
tings. Certainly, more investigation is required to study
the dynamics of these newly identified subtypes during
helminth infection, and in particular to compare and
contrast the phenotypes of Tregs induced by helminths
migrating through, or establishing in, different tissues
such as the skin, lungs, vasculature and intestinal tract.
Therapeutic potential – epidemiological evidence
in humans
As discussed above, regulatory T-cells may protect the
host against the excessive immunopathological responses
to helminth infection, and maintain an immunological
compromise that benefits host health while tolerating
some degree of parasite infestation. The promotion of
regulatory T-cells by helminths may have further, albeit
less expected, beneficial effects for the host by downregu-
lating responsiveness to other coinciding antigens, and
therefore reducing the impact of allergens, autoantigens
and other infectious agents. This is one strand of the pos-
tulated ‘hygiene hypothesis’, which would be consistent
with experimental and epidemiological evidence gathered
from both mouse and human studies.72,73
Several studies have reported that helminth-infected
individuals have a lower allergic response to allergens,
such as the house dust mite (HDM), as is the case for
children infected with Schistosoma haematobium74,75 and
S. mansoni.76,77 This effect is further supported by an
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Figure 2. Tregs in response to helminth infection in different tissues. Liver, upregulation of GITR, CD103 and CTLA-4 on Tregs in response to
Schistosoma mansoni infection and exposure to eggs trapped in the liver; peritoneal cavity, CD103 and CTLA-4 on Tregs are upregulated when
infected with the filarial nematode Brugia malayi; large intestine, increase in CD103 expression on Tregs in mice carrying duodenal infection with
Heligmosomoides polygyrus, Treg expression of RORct and ST2 are as yet unknown during helminth infection; pleural cavity, Litomosoides sigmod-
ontis infection upregulates ICOS, GITR, PD-1 and CTLA-4 expression on Tregs; spleen, S. mansoni infection increases the expression of GITR
and CTLA-4 on Tregs; small intestine, Trichinella spiralis infection induces high levels of CTLA-4 expression on Tregs and H. polygyrus infection
upregulates CD103 and CTLA-4 as measured on Tregs in the mesenteric lymph nodes, a surrogate of the populations in the small intestine lam-
ina propria. CTLA-4, cytotoxic T-lymphocyte-associated protein 4; GITR, glucocorticoid-induced tumour necrosis factor receptor; ICOS, induci-
ble T-cell co-stimulator; PD-1, programmed cell death protein 1; RORct RAR-related orphan receptor gamma.
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enhancement of skin test reactivity in children following
anthelmintic treatment, providing evidence of causality
between helminth infection and reduced allergy,78,79 Stud-
ies in which pregnant mothers were treated with anthel-
mintics, in the hopes that parasite elimination would
reduce maternal anaemia and enhance fetal growth,
showed that there was actually a significant adverse effect
with increased rates of infantile eczema.80,81 It is impor-
tant to note that particular helminth species can be more
strongly linked to a protection against allergy, such is the
case for hookworm, and that the intensity of the infection
may also be key to the protective effects. Together these
studies, and others, built a body of evidence that hel-
minths exert a protective effect against allergies and pro-
vide an environmental explanation for higher levels of
eczema and asthma in the developed world.82!84
While there has been a parallel increase in the inci-
dence of autoimmune diseases in developed countries,
there is sparse epidemiological evidence for parasite
immunosuppression reducing autoimmunity. Levels of
auto-reactive anti-nuclear antibodies (ANA), which are
central for the diagnosis and classification of autoimmune
diseases, were found to be lower in individuals infected
with S. haematobium compared with age-matched unin-
fected cohabitants. Moreover, 6 months after anti-hel-
minthic treatment, levels of ANA significantly increased,
implying that the parasite is able to generate conditions
in which autoimmunity is suppressed.85 The most striking
indication of Treg involvement in helminth protection
against autoimmunity was determined in a multiple scle-
rosis (MS) patient cohort in Argentina, in which MS
patients unintentionally acquired gastrointestinal hel-
minth infection with a variety of species. Those infected
had increased TGF-b and IL-10 levels, as well as elevated
Treg and Breg activity. The infected patients also showed
significantly lower numbers of disease exacerbations and
fewer magnetic resonance imaging (MRI) lesion changes
in comparison to uninfected MS patients over the same
period of time.86 A small number of these patients were
subsequently given anti-parasitic treatment, which leads
to an increase in clinical and radiological disease. This
increase in MS severity was also associated with a reduc-
tion in TGF-b- and IL-10-secreting cells and reduced
FOXP3+ Tregs within 3 months post-anthelmintic treat-
ment.87
Although we have highlighted particular studies indi-
cating that helminth infection may protect against inflam-
matory diseases, there are also instances in which worms
may exacerbate disease. In a mouse model setting,
H. polygyrus promotes colon cancer following DSS-driven
inflammation61 and enhances colitis provoked by
Citrobacter infection.88 In humans, anthelmintic treatment
of individuals in an area highly prevalent for Ascaris
resulted in an overall improvement of asthma within the
population.89 This further highlights the double-edged
nature of live parasites and the benefits of identifying
individual molecular products that induce Tregs, which
can then be used as a therapeutic treatment for inflam-
matory diseases in the future.
Evidence for a role of helminth Tregs in suppression
of inflammatory disease
To clarify the role Tregs may be playing in the helminth-
induced bystander immunosuppression, we look to
mouse models of disease. Helminths have been used in a
range of autoimmune or allergy models, showing that
parasites are able to successfully suppress inflammatory
diseases, as recently summarized by fellow colleagues90,91
and ourselves.92 These studies have determined that Tregs
are an important cell type mediating helminth protection,
although in some models helminth protection is Treg-, or
even T-cell-independent, indicating that the mechanism
of protection may be parasite and disease model specific.
In H. polygyrus a role for Tregs have been demon-
strated for immune suppression in a range of different
disease models, including allergic airway inflammation
with HDM, ovalbumin (OVA)-specific airway allergy,
type 1 diabetes in non-obese diabetic (NOD) mice and
inflammatory bowel disease.93!95 Similarly, during
S. mansoni infection there is evidence to suggest Tregs
play a role in suppression of OVA-specific airway inflam-
mation, and in some studies protection is both T-cell and
IL-10-dependent, indicating that Tr1 cells may also be
important immune regulators during helminth infec-
tion.84,96,97
Human helminth therapy trials – past, present
and future?
Deliberate infection of humans with helminths to dampen
inflammatory disorders has been mooted for several dec-
ades, ever since a report that self-infection with Necator
americanus hookworms abolished hay fever.98 Such anec-
dotal reports continue, with for example a colitis sufferer
showing benefit from self-treating with the human whip-
worm Trichuris trichiura.99 More controlled trials of live
helminth therapy started in 2006 using the pig whip-
worm, Trichuris suis, which establishes a transient infec-
tion in humans, and potentially less pathogenic than
human-infective helminth species; furthermore, T. suis
ova (TSO) administration successfully treated a macaque
monkey colony suffering idiopathic bowel dysfunction.100
Notably, in neither of these studies did Trichuris spp.
infection raise expression of FOXP3+ Tregs, which were
generally found to be more frequent in inflammation
than in healthy tissues and controls.
Early, small-scale trials of TSO in Crohn’s disease and
ulcerative colitis provided promising results,101,102 fol-
lowed by larger clinical trials not only for IBD, but also
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rhinitis and MS, which have recently been reviewed by a
number of authors;103!108 helminth therapy has even
extended to autism.109 The outcomes for inflammatory
bowel disease (IBD) and MS remain inconclu-
sive,106,110,111 with modest effects at best,112 and generally
falling short of statistical significance. However, a signifi-
cant benefit was found for hookworm treatment of
patients with Coeliac disease, many of whom regained
gluten tolerance, accompanied by a significant increase in
FOXP3+ Tregs among the intraepithelial lymphocytes,113
although not in peripheral blood.114
Several commentators have identified reasons why hel-
minth therapy has been less efficacious than may have
been hoped, focussing on whether early-age, longer-term
and/or higher-intensity infections may be required,105
whether a human parasite is more appropriate than a
porcine one,104 if the entirely enteric location of whip-
worms lacks a systemic presence and, perhaps most
uncertain, whether the human immune system varies sig-
nificantly in responses to helminth infection.115 As yet,
there appears to be no common immunoregulatory path-
way invoked by experimental human helminth infection,
with the paucity of evidence for Treg involvement being
perhaps the most surprising.
Overall, helminth therapy for human inflammatory dis-
orders holds some important lessons, and some caveats,
for the future. Live infection remains an imperfect art,
with parasite biology dictating dose, longevity and loca-
tion of the therapeutic agents; these agents, presumed to
be secreted products, are themselves poorly defined as are
the host targets of parasite immune modulation. Hence,
while recent work has provided proof-of-concept that hel-
minths may offer innovative anti-inflammatory treat-
ments, further advances now require identification of
helminth modulatory molecules and their modes of
action, so that rational and defined new pharmaceutics
can be developed for therapy.
Moving forward into the molecular era
A number of exciting parasite proteins have recently been
identified as potential immune modulators for inflamma-
tory disease;48 however, for the purpose of this review we
will focus on molecules that exert their effects through
Tregs, either directly or indirectly. HES are capable of
directly inducing Tregs in vitro that effectively suppress
both in vitro effector cell proliferation as well as in vivo
allergic airway inflammation.50 As mentioned earlier, the
component within HES has been identified as Hp-TGM
and signals through TGF-b receptors to induce Foxp3+
Tregs in vitro. In a model of allograft rejection, mice
receiving Hp-TGM or HES had an extended median sur-
vival with reduced inflammation and elevated Foxp3+
Treg numbers in the allograft draining lymph nodes com-
pared with controls.51 Interestingly, manipulation of the
TGF-b pathway is not unique to H. polygyrus, with active
ligands identified from other helminth species.48,90,116
While examples of helminth molecules directly driving
Treg differentiation remain few, a greater range of hel-
minths appear to induce Tregs indirectly. The proteome
analysis of the hookworm Anyclostoma caninum revealed
two proteins named anti-inflammatory protein (AIP)-1
and AIP-2 that were subsequently identified as having
immunosuppressive properties. Intraperitoneal adminis-
tration of AIP-1 was shown to limit inflammatory cell
infiltrate, increased IL-10 and TGF-b production, and
recruited Tregs to the site of inflammation in a mouse
model of colitis.117 On the other hand, AIP-2 was effec-
tive at suppressing inflammation and pathology in a
mouse model of asthma, and expansion of CD11c+ DCs
and Foxp3+ Tregs were essential for this disease protec-
tion.118 The study by Navarro et al. also showed that
AIP-2 suppressed the proliferation of T-cells from
patients with HDM allergy ex vivo indicating that this
protein might be a potential therapeutic for allergic
asthma in humans.
Similarly, S. mansoni SEA are capable of protecting
NOD mice against the development of type-1 diabetes in
a Treg-dependent manner. This was indicated as spleno-
cytes from SEA-treated mice were unable to transfer dia-
betes, whereas splenocytes that were CD25+ T-cell
depleted had a restored ability to transfer diabetes.53 The
SEA contains a well-characterized glycoprotein, x-1, that
is able to drive Foxp3+ Treg numbers, and NOD mice
immunized with x-1 were also protected from diabetes.
It has been identified that x-1 induces Foxp3 expression
in NOD mouse CD4+ T-cells through the induction of
tolerogenic DCs that produce TGF-b and retinoic acid.55
Many helminths secrete cysteine protease inhibitors
(CPIs) with immunomodulatory properties.119,120 A
recent study on recombinant Ascaris lumbricoides rA1-CPI
in a mouse model of allergic airway inflammation with
HDM showed that rA1-CPI reduced airway inflammation
and hyper-reactivity. A significant reduction in Th2
cytokines and increased Tregs in spleen, as well as
increased IL-10 levels in the bronchoalveolar lavage and
splenocyte cultures in rA1-CPI-treated mice compared
with controls. Furthermore, this effect was partially
blocked by anti-IL-10-receptor suggesting the disease sup-
pression seen is in part mediated through IL-10 sig-
nalling.121
These parasite-derived proteins could be used to induce
Foxp3 expression in vivo, making them excellent candi-
dates for use in clinical trials on inflammatory diseases in
which Treg numbers are reduced or dysfunctional. Fur-
thermore, molecules such as Hp-TGM have no structural
homology to mammalian TGF-b therefore, unlike native
TGF-b, may retain biological activity for a long period of
time. Although the use of parasite molecules in place of
the helminth itself may prove to be a fruitful venture for
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clinical therapy, the induction or expansion of Foxp3+
Tregs by parasite molecules in vitro and subsequent trans-
plantation into diseased patients may be another path
worth exploring.
Will trials with helminth-induced Treg transfer
be effective?
Given that clinical trials with live parasites have shown
very little consistency in inflammatory disease thus far,
future studies may be directed towards the use of hel-
minth products for Treg transfer clinical trials. Animal
models have identified that adoptive transfer of Tregs
from S. mansoni- or H. polygyrus-infected mice can pro-
tect against inflammatory disease, suggesting these cells
can exert systemic down-modulation of bystander
immunopathologies.50,53,93 Moreover, a major challenge
in Treg therapy is to direct cells to the site of inflamma-
tion, and that they mediate the appropriate suppressive
mechanism required to treat the disease in question.122
Given that some helminth products induce RA, which is
important for the upregulation of gut-homing receptors
such as CCR9 and integrin-a4b7, this may be advanta-
geous for Treg therapeutics in IBD in trafficking cells to
the site of inflammation.55,123 Additionally, as discussed
earlier in the review, Tregs during helminth infection
express high levels of CTLA-4, PD-1 and ICOS on their
surface, indicating that these cells potentially represent a
more active Treg population that would be efficient sup-
pressors of inflammatory diseases.
Currently, there are several concerns about the efficacy
and risks of Treg therapy in humans. An overactive Treg
compartment might compromise immunity to other infec-
tions, or even permit outgrowth of tumours, in a reverse
scenario to strategies targeting Tregs for cancer control.124
A more subtle concern for Treg therapy following ex vivo
conversion and return to the same patient, is whether the
injected Treg population will retain suppressor properties
or if they will be converted into effector cells. Some studies
have looked at the nTreg population switching to Th17
cells in the presence of IL-6, rendering them a problematic
population in autoimmune diseases such as rheumatoid
arthritis and MS that are characterized by auto-reactive
Th17 cells.125 However, the pre-treatment of these cells
with IL-2, TGF-b and/or RA make these cells resistant to
effector cell conversion and allows them to retain suppres-
sive properties.126,127 This therefore identifies an area in
which helminth products may be used to stabilize nTreg
populations ex vivo, allowing them to remain potent
immunosuppressors once transplanted.
To date, Treg transfer clinical trials have focused on
ex vivo expansion of pre-existing nTregs and implanting
them back into patients,128 while very little work has been
done on converting na€ıve T-cells, or even pro-inflamma-
tory effector T-cells, into Tregs before implantation. This
could be a new area of research for helminth products.
An advantage of inducing Tregs from na€ıve or effector
CD4+ T-cells is the generation of antigen-specific Tregs,
which may be directed toward the suppression of a speci-
fic autoimmune disease, and which may be absent from
the pre-existing nTreg population within the patient. Fur-
thermore, as several inflammatory diseases are associated
with a deficient number of nTregs, the ability to induce
stable autologous Tregs from na€ıve CD4+ T-cells would
be an improvement on current Treg therapeutic options.
Conclusion
The world of helminths has opened many new perspec-
tives on immune regulation in general and Tregs in par-
ticular. Animal models have shown strong evidence that
helminthic therapy can treat and/or prevent inflammatory
diseases with some models dependent on Tregs; however,
thus far the human clinical trials have been lacking in
consistency or efficacy. Therefore we suggest that in the
coming years the focus should be switched to individual
helminth products as they provide a safer, more defined
and directable therapeutic compared with live infection.
Of particular interest are compounds that play a key role
in the immunoregulatory network, either directly or indi-
rectly inducing and expanding Tregs either ex vivo or
in vivo, and with potential to stabilize and promote the
function of this cell type as a future therapy across a
broad range of chronic inflammatory conditions.
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